EXHIBIT B



REFERENCES CONSIDERED BY DR. EDUARDO A. PADLAN

Exhibit No.	<u>Description</u>
1001	U.S. Patent No. 6,407,213, Method for making humanized antibodies (filed Jul. 17, 1993) (issued June 18, 2002)
1002 Part I	File History for U.S. Patent No. 6,407,213 Part I
1002 Part II	File History for U.S. Patent No. 6,407,213 Part II
1003	Declaration of Dr. Eduardo A. Padlan in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213
1003A	Curriculum Vitae of Dr. Eduardo A. Padlan
1003B	Materials Reviewed by Dr. Eduardo A. Padlan
1003C	Exhibits A-M of Dr. Eduardo A. Padlan
1004	Declaration of Professor Edward Ball, M.D. in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213
1004A	Curriculum Vitae of Professor Edward Ball, M.D.
1004B	Materials Reviewed by Professor Edward Ball, M.D.
1021	Hudziak et al. p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor. Mol. Cell Biol. 9(3):1165-1172 (March 1989)
1022	Köhler and Milstein, Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (August 7, 1975)
1030	"Protein Data Bank – Chronology" at https://www.nsf.gov/news_summ.jsp?cntn_id=100689 (accessed August 29, 2016)
1031	Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region



Exhibit No.	<u>Description</u>
	Domains. Pro. Nat'l Acad. Sci. 81:6851-6855 (November 1984).
1033	Jones et al. Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse. Nature 321:522-525 (1986)
1034	Queen et al. A Humanized Antibody that Binds to the Interleukin 2 Receptor. Pro. Nat'l Acad. Sci. 86:10029-10033 (1989)
1045	Slamon, D.J. et al. <i>Human Breast Cancer Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene</i> . Science 235:177-182 (1987)
1046	Kraus, M.H., et al. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. The EMBO Journal 6(3):605-610 (1987)
1047	Hudziak, R. M., et al. <i>Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells</i> . Pro. Nat'l Acad. Sci. 84:7159-7163 (1987)
1048	Shepard, H. M. et al. <i>Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the clinic</i> . Journal of Clinical Immunology, 11(3):117-127 (1991).
1049	Chothia, C. et al. <i>Conformations of immunoglobulin hypervariable regions</i> . Nature 342(21):877-883 (December 1989).
1050	Queen, Cary L.: International Publication No. WO 1990/07861 (published July 26, 1990)
1051	Tramontano, A. et al. Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the V_H Domains of Immunoglobulins, J. Mol. Biol. 215:175-182 (1990)
1052	Kabat, et al. Sequences of Proteins of Immunological Interest 4 th



Exhibit No.	<u>Description</u>
	Ed., Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens (National Institutes of Health, Bethesda, Md.) (1987)
1053	Wu and Kabat, An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132:211-250 (1970)
1055	Kabat, et al. Sequences of Proteins of Immunological Interest 5 th Ed., Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens (National Institutes of Health, Bethesda, Md.) (1991)
1057	Johnson and Wu <i>The Kabat database and a bioinformatics</i> example, Methods in Molecular Biology 248:11-25 (December 2003)
1058	Davies & Metzger, Structural Basics of Antibody Function, Annu. Rev. Immunol. 1:87-117 (1983)
1059	Amit et al. Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution Science 233:747-53 (1986)
1060	Lascombe et al. Three-dimensional Structure of Fab R19.9, a Monoclonal Murine Antibody Specific for the pazobenzenearsonate group. Pro. Nat'l Acad. Sci. 86:607-611 (January 1989)
1061	Novotný et al. <i>Molecular Anatomy of the Antibody Binding Site</i> . J. Biol. Chem. 258(23):14433-14437 (December 10, 1983)
1062	Chothia & Lesk 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196:901-917 (1987)
1063	Chothia et al. <i>Domain Association in Immunoglobulin Molecules: The Packing of Variable Domains</i> . J. Mol. Biol. 186:651-63 (1985)



Exhibit No.	<u>Description</u>
1064	Van Kroonenburgh & Pauwels <i>Human Immunological Response</i> to Mouse Monoclonal Antibody Treatment or Diagnosis of Malignant Diseases. Nucl. Med. Commun. 9:919-30 (1988)
1065	Tjandra et al. <i>Development of human anti-murine antibody</i> (HAMA) response in patients. Immunol. Cell. Biol. 68:367-76 (1990)
1066	Lind, et al. Development of human antimouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibod. Immunoconj. Radiopharm. 4(4):811-818 (1991)
1067	Mountain and Adair, <i>Engineering Antibodies for Therapy</i> . Biotech. Genet. Eng. Rev. 10:1-142 (1992)
1068	Verhoeyen, Milstein & Winter et al. Reshaping Human Antibodies: Grafting an Antilysozyme Activity. Science 239:1534-1536 (March 25, 1988)
1069	Riechmann, et al. <i>Reshaping human antibodies for therapy</i> . Nature 332:323-327 (March 24, 1988)
1070	Tempest, et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. BioTechnology 9:266-271 (March 1991)
1071	Kurrle, et al. <i>Improved monoclonal antibodies against the human alphabeta T-Cell receptor, their production and use.</i> EP0403156. (1990)
1072	Shearman, et al. Construction, expression and characterization of humanized antibodies directed against the human a/b T cell receptor. J. Immunol. 147(12):4366-4373, (December 15, 1991)
1073	Winter, Gregory Paul et al. EP Publication Number 0239400, <i>Recombinant antibodies and methods for their productions</i> . Published September 30, 1987.



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

